**Core tip:** Acute myocardial infarction is the leading cause of death in the world. At least half of the resulting myocardial damage is associated with myocardial reperfusion. Myocardial reperfusion injury is associated with reactive oxygen species production and iron mobilization. Treatment with antioxidants such as ascorbate, N-acetylcysteine, and an iron chelator such as deferoxamine, could prevent the development of this damage.

INTRODUCTION
============

Acute myocardial infarction (AMI) is the leading cause of death worldwide, and it is associated with high morbidity and mortality. The AMI complications have significantly decreased with the development of interventional cardiology and percutaneous coronary angioplasty (PCA) treatment, which quickly and effectively restore the blood flow to the area previously subjected to ischemia\[[@B1]\]. Paradoxically, the restoration of blood flow to the ischemic zone leads to a massive production of reactive oxygen species (ROS), which generate rapid and severe damage to biomolecules, in a phenomenon called myocardial reperfusion injury (MRI)\[[@B2],[@B3]\]. Sources of ROS in reperfusion include the predominant contribution of NADPH oxidases, which are present in many cell types in myocardial tissue. Other sources are xanthine oxidase, uncoupled eNOS and the mitochondrion\[[@B4]\]. In the clinical setting, MRI is associated with multiple complications such as lethal reperfusion, no-reflow phenomenon, myocardial stunning, and reperfusion arrhythmias (Figure [1](#F1){ref-type="fig"}).

![Generation of reactive oxygen species and mobilization of iron after myocardial reperfusion. There is a massive production of reactive oxygen species and iron mobilization by the different cellular types of the myocardial tissue. The iron reacts with superoxide anion to produce hydroxyl radical by the Fenton reaction. Inside cardiomyocyte, there is intracellular production of reactive oxygen species through NADPH oxidase, eNOS uncoupled, xanthine oxidase and mitochondrion. NOX: NADPH oxidase; ROS: Reactive oxygen species; Fe: Iron; eNOS: Endothelial nieric oxide synthases.](WJC-10-74-g001){#F1}

Despite significant advances in the understanding of the mechanisms accounting for MRI, it remains an unsolved problem. Although promising results have been obtained in experimental studies (mainly in animal models) these benefits have not been translated into clinical settings. Clinical trials have failed to find benefits from any therapy to prevent MRI, demonstrating a clear dissociation between the bench and the bedside\[[@B5]\].

Prevention of MRI in the clinical setting has intrinsic difficulties in its approach. First, any therapy oriented to MRI prevention must be administered prior to myocardial reperfusion (in other words, prior to PCA). In addition, it should be applied in doses high enough to counterbalance the rapid and massive ROS production following reperfusion. Moreover, there are many different visions regarding the best biomarker to define MRI in patients, and so clinical trials express their results with different outcomes (such as clinical outcomes, serum cardiac biomarkers, echocardiographic parameters, cardiac magnetic resonance, among many others) which makes the analyses even more difficult. All these elements have made it difficult to develop an effective therapy to prevent MRI in AMI patients. The present review focuses on the cellular and molecular mechanisms of oxidative-stress induced MRI during AMI, and the key points to develop an appropriate strategy to reduce oxidative damage derived from myocardial reperfusion.

PATHOPHYSIOLOGY
===============

MRI is a clinical problem associated with procedures such as thrombolysis, angioplasty, and coronary bypass surgery, which are commonly used to re-establish the blood flow and minimize the damage to the heart due to severe myocardial ischemia\[[@B3]\]. There are three main hypotheses which have been proposed to explain the pathogenesis of ischemia reperfusion (IR) injury: oxidative stress, iron mobilization, and Ca^2+^-overload\[[@B6],[@B7]\]. All of these mechanisms are most likely related, but it is not known whether they operate simultaneously or one precedes the other (Figure [2](#F2){ref-type="fig"}).

![Role of reactive oxygen species and iron mobilization in myocardial reperfusion injury and its clinical implications. MVO: Microvascular obstruction; ONOO\*: Peroxynitrite; NO: Nitric oxide; OH \*: Radical hydroxyl; Fe: Iron; RyR: Ryanodine receptor channel; SERCA: Sarco/endoplasmic reticulum Ca^2+^-ATPase.](WJC-10-74-g002){#F2}

Oxidative stress
----------------

The level of myocardial tissue oxygenation increases following restoration of blood flow, which is initiated with a burst of ROS generation\[[@B8]\]; these ROS are the major initiators of myocardial damage in MRI\[[@B3]\]. Increased ROS production is mainly due to the activation of xanthine oxidase in endothelial cells, mitochondrial electron transport chain reactions in cardiomyocytes, and NADPH oxidase in inflammatory cells\[[@B9]\] (Figure [1](#F1){ref-type="fig"}).

Oxidative stress occurs when there is an imbalance between the generation of ROS and the antioxidant defense systems in the body so that the latter becomes overwhelmed\[[@B10]\]. ROS include hydrogen peroxide (H~2~O~2~), the superoxide radical anion, the hydroxyl radical (OH^•^), and peroxynitrite anion (ONOO^-^), and they have all been shown to increase with reperfusion\[[@B11]\] (Figure [2](#F2){ref-type="fig"}). As a result of lipid peroxidation, oxidation of DNA and proteins and membrane damage may take place. This leads to alterations in membrane permeability and to modifications of protein structure and functional changes\[[@B12]\].

**ROS sources:** In pathophysiological conditions, there are many sources of ROS in myocardial tissue. The most important sources are NADPH oxidases (NOX), uncoupled eNOS, xanthine oxidases and the mitochondrion. NOX catalyzes the one electron reduction of O~2~ to generate super-oxide radical anion (O~2~^•−^), using NADPH as the source of electrons. This enzyme is largely present in the activated neutrophil, wherein it generates large amounts of toxic O~2~^•−^ and other ROS important in bactericidal function\[[@B13]\]. Pathogenic roles of NOX-derived ROS are also verified in human IR injury *in vivo*\[[@B14]\]. It was recently reported that in isolated perfused murine hearts that *NOX1* and/or *NOX2* gene knock-out significantly attenuated MRI (by up to 50% of the final infarct size)\[[@B15]\], thus demonstrating the crucial importance of this enzyme in MRI.

The NO synthases (NOS) are a family of enzymes that convert the amino acid L-arginine to L-citrulline and NO. Endothelial NOS (eNOS) plays a major role in the regulation of vascular function. The eNOS may become uncoupled in the absence of the NOS substrate L-arginine or the cofactor BH4. Uncoupled eNOS results in the production of O~2~^•−^ instead of NO\[[@B16]-[@B18]\]. This perpetuates a vicious cycle because peroxynitrite, the reaction product of superoxide and NO, leads to further eNOS uncoupling\[[@B19]\]. Furthermore, eNOS uncoupling may play a major role in MRI by increasing ROS production and limiting NO availability\[[@B20]\].

Xanthine oxidase is predominantly present in the vascular endothelium in the normal heart and generates O2^•−^, H~2~O~2~, and OH^•^ as byproducts of its normal metabolic action\[[@B21]\]. Under pathological conditions, such as tissue ischemia, xanthine dehydrogenase can be converted to Xanthine oxidase. In IR this enzyme catalyzes the formation of uric acid with the coproduction of O2^•−\[22\]^. Superoxide release results in the recruitment and activation of neutrophils and their adherence to endothelial cells, which stimulates the formation of xanthine oxidase in the endothelium, with further O2^•−^ production\[[@B23]\]

Mitochondria are cellular organelles involved in energy production, so any injury that they may suffer could cause impairment of cellular energy that could lead, depending on the intensity of the injury, to apoptosis or different levels of cellular damage. During ischemia, due to the lack of oxygen, the electron transport chain cannot function correctly and therefore ROS are produced at high levels. Additionally, ROS may cause oxidative damage of mitochondrial DNA, impairing mitochondrial function. This damage performs a positive feedback on ROS production that, at the same time, perpetuates mitochondrial damage and ROS synthesis. Oxidative injury to the mitochondrial membrane can also occur, resulting in membrane depolarization and the uncoupling of oxidative phosphorylation, with altered cellular respiration\[[@B24]\]. This can ultimately lead to mitochondrial damage, with release of cytochrome c, activation of caspases, and apoptosis\[[@B25]\].

**RNS sources:** The ROS are not solely responsible for free radical damage. Reactive nitrogen species (RNS), mainly peroxynitrite anions (ONOO-), also generate RNS-damage, thus producing nitrosative stress. Peroxynitrite results from the interaction between NO and the superoxide anion\[[@B4]\], and NO is synthesized mainly by nitric oxide synthases which have two isoforms in the cardiomyocyte: endothelial (eNOS) and inducible (iNOS). Oxidative and nitrosative damage causes the uncoupling of both NOS isoforms, resulting in the enhanced synthesis of O2^•−\[4\]^.

Evidence supports the view that nitrosative stress plays an important role in the pathogenesis of MRI. While NO itself is not harmful, some of the reaction products (mainly OH^•^) resulting from high ONOO- formation in the cell are highly cytotoxic substances\[[@B26]\]. The production of O2^•−^ is increased during reperfusion, which interacts with NO and leads to the formation of ONOO-, thus triggering the previously described phenomenon\[[@B27]\]. Peroxynitrite not only causes structural damage by attacking macromolecules, but it also leads to myocardial functional impairment\[[@B28]\]. The general view about the mechanisms that lead to nitrosative stress is that IR can induce iNOS expression and that the resulting high concentrations of NO can lead to cardiac injury\[[@B26]\]. The drop in NO concentration occurring during cardiac IR plays an important role in triggering the transcription nuclear factor kappaB (NF-κB) leading to activation and successive induction of iNOS expression during the reperfusion phase\[[@B29]-[@B31]\]. Figure [1](#F1){ref-type="fig"} shows a diagram of ROS and RNS sources in myocardial tissue.

Iron mobilization
-----------------

It has been postulated that iron homeostasis could play an important role in the development of MRI in the cardiomyocytes\[[@B32],[@B33]\]. Free iron is deleterious for cells; thus generally it is bound to proteins forming complexes\[[@B34]\]. During ischemia, iron metabolism is impaired, and it is released as free iron. This catalytic free iron can generate ROS through the Fenton reaction, catalyzing the production of ·OH from H~2~O~2~ and O~2~^•−\[35\]^. It has been reported that susceptibility to injury from H~2~O~2~ in rat hearts is associated with the magnitude of the intracellular low molecular weight iron pool\[[@B36]\]. Some metals with redox properties have a well-documented role in the development of MRI\[[@B37],[@B38]\]. Following reperfusion, both iron and copper are released to the coronary circulation\[[@B32]\] which can contribute to ROS generation (Figure [2](#F2){ref-type="fig"}). In patients with thalassemia the iron overload is related to arrhythmias and congestive heart failure, which is the main cause of death among these patients\[[@B39]\]. Iron chelation therapy has significantly improved the survival of patients with thalassemia\[[@B40]\], because iron chelators are effective and safe drugs to treat the iron poisoning\[[@B41]\].

Calcium homeostasis
-------------------

Oxidative stress modifies phospholipids and proteins leading to lipid peroxidation and thiol-group oxidation; these changes are considered to alter membrane permeability and configuration in addition to producing functional modifications of various cellular proteins\[[@B42]\]. Oxidative stress may result in cellular defects including a depression in the sarcolemma Ca^2+^-pump ATPase that leads to a decreased Ca^2+^-efflux, and a depression in (Na + K)-ATPase activity that, in turn, leads to an increased Ca^2+^-influx\[[@B43]\]. Oxidative stress has also been reported to depress the sarcoplasmic reticulum Ca^2+^-pump ATPase (SERCA) and thus inhibit Ca^2+^ sequestration from the cytoplasm in cardiomyocytes\[[@B44]\]. The depression in Ca^2+^-regulatory mechanism by ROS ultimately results in intracellular Ca^2+^ (\[Ca^2+^\]i) overload and cell death. In addition, an increase in \[Ca^2+^\]i during ischemia induces the conversion of xanthine dehydrogenase to xanthine oxidase and subsequently results in increased production of O~2~^•−\[44\]^.

Recently it has been shown that the function of the channel ryanodine receptor (RyR) is controlled by ROS\[[@B45]\]. It has been demonstrated that NADPH oxidase and the RyR channel could be located adjacent to each other in the T-tubules of cardiomyocytes\[[@B46]\]. Thus, the increase in ROS production after myocardial reperfusion could lead to an increase in RyR channel function, resulting in an intracellular calcium overload, thereby causing activation of pro-apoptotic intracellular pathways, necrosis, and electromechanical alteration. All these mechanisms are summarized in Figure [3](#F3){ref-type="fig"}.

![Central role of calcium in the electro-mechanical dissociation of cardiomyocyte after myocardial reperfusion. RyR: Ryanodine receptor channel; SERCA: Sarco / endoplasmic reticulum Ca^2+^-ATPase; mPTP: Mitochondrial permeability transition pore; Ca: Calcium; ROS: Reactive oxygen species.](WJC-10-74-g003){#F3}

**Redox-sensitive signaling pathways**: Not only do ROS exert their actions by directly modifying organic molecules, but ROS are also involved in the regulation of the expression of several genes\[[@B47]\]. NF-ĸB and AP-1, both of which can experience ROS-mediated activation, stimulate the transcription of several protein mediators, for example, proinflammatory cytokines that activate several cell death pathways\[[@B48]\]. The role of cytokines, chemokines, leukocytes, and acute-phase proteins such as high-sensitivity C-reactive protein in the pathogenesis of MRI has been reported in several studies\[[@B49],[@B50]\]. Oxidative stress, ROS and inflammation are linked in a way that is very difficult to dissect. These phenomena have important molecular bridges that are activated in the presence of ROS\[[@B51]\], leading to the activation of multiple mechanisms that cause heart tissue remodeling and therefore enhance the susceptibility to rhythm disorders. Among those molecules, the most studied has been the transcriptional factor NF-ĸB, a factor that responds to changes of the cellular oxidative state, ischemia-reperfusion, and inflammatory molecules\[[@B52]\]. When NF-ĸB is activated, for example in the presence of ROS by phosphorylation of its inhibitory cofactor (Iĸ-B), it bonds to a DNA response element and promotes the transcription of genes involved in inflammatory and pro-fibrotic response, for example IL-6, which transforms growth factors TGF-β and TNF-α\[[@B53]\]. Those molecules act in various tissues, but particularly in the heart, producing extracellular matrix remodeling and fibrosis (structural remodeling), which changes the electrophysiological properties of the heart. Several studies have associated NF-ĸB activation with cardiac dysfunction, ventricular hypertrophy, and maladaptive cardiac growth\[[@B54]\] (Figure [2](#F2){ref-type="fig"}).

Exposure to low-to-moderate ROS levels should trigger a survival response and reinforce ROS scavengers of the antioxidant defense system to elicit a cardioprotective effect for myocardial reperfusion. The molecular mechanism responsible for this adaptive change involves enhanced antioxidant activity achieved by up-regulating several housekeeping genes partly under the control of Nrf2 (nuclear factor-erythroid 2-related factor 2); Nrf2 is normally sequestered in the cytosol by Keap\[[@B55]\]. Upon oxidative stimulation, Nrf2 oxidizes or covalently modifies Keap1 thiol groups, which dissociate from Keap1 and undergo nuclear translocation. In the nucleus, Nrf2 binds to antioxidant response elements in target gene promoters\[[@B56]\], which increase the expression of antioxidant enzymes. It has been demonstrated that the constitutive levels/activities of a number of important antioxidants and phase 2 enzymes, such as CAT, GSH-Px, glutathione reductase, glutathione transferase, NADPH-quinone oxidoreductase 1, and heme oxygenase-1 in primary cardiomyocytes are dependent on Nrf2 status. In addition, Nrf2 diminishes the susceptibility of cardiomyocytes to injury elicited by oxidants and electrophilic species\[[@B57]\], making the Nrf2 signaling pathway an important mechanism for myocardial cytoprotection. It is of interest to note that ROS levels could be responsible for the activation of NF-κB and/or Nrf2 pathways.

**Clinical implications:** Myocardial damage caused by ischemia-reperfusion events are mainly associated with four clinical conditions: lethal reperfusion, myocardial stunning, no-reflow phenomenon, and reperfusion arrhythmias (Figure [2](#F2){ref-type="fig"}).

Lethal reperfusion is a paradoxical type of MRI caused by the restoration of coronary blood flow after an ischemic episode. It is defined as the death of cardiomyocytes that were viable immediately before myocardial reperfusion. Its main manifestation is as an increased infarct size due to reperfusion, a condition mainly associated with AMI\[[@B3]\]. In the late fifties, it was suggested that myocardial reperfusion contributes part of the histological damage associated with ischemia-reperfusion models. However, for decades it was very complex to determine the precise evolution of necrosis along the transition from ischemia to reperfusion in myocardial tissue\[[@B58]\]. Nowadays, the harmful effects of myocardial reperfusion damage, also known as lethal reperfusion injury, are considered to involve myocardial cell death derived from the restoration of blood flow subsequent to an ischemic process, and to act through mechanisms strongly associated with oxidative stress\[[@B3]\].

Reperfusion arrhythmias clinically represent a major comorbidity of AMI with an 88.7% occurrence rate in certain small clinical trials with continuous monitoring\[[@B59]\]. In addition, postoperative atrial fibrillation (POAF), the most common reperfusion arrhythmia associated with cardiac surgeries, has an incidence ranging between 20%-40%\[[@B60]\]. Myocardial stunning, despite being a reversible damage, is the cause of an impaired ventricular function that leads to increased morbidity. It is derived from a short-term ischemia-reperfusion process that was first reported in the early 1930s\[[@B61]\]. Myocardial stunning is present to a greater or lesser extent in all survivors of AMI. In the late 1980s evidence began to appear suggesting an important role of oxidative stress in the development of myocardial stunning, proposing that the main injury pathway could be an altered calcium homeostasis associated with sarcoplasmic reticulum damage\[[@B62]\]. More recently, clinical studies have strengthened this hypothesis\[[@B63]\], and it has been reported in animal models that interventions aimed to improve antioxidant defenses attenuate myocardial stunning\[[@B64],[@B65]\].

The no-reflow phenomenon is an impaired myocardial perfusion of a specific segment of the coronary system that is not associated with an angiographic occlusion of the respective vessel\[[@B66]\]. Vascular and endothelial damage can occur after the reperfusion of previously blocked coronary circulation. It can be exhibited as a microvascular dysfunction after restoring the flow during either angioplasty or thrombolysis, thus leading to the development of the no-reflow phenomenon\[[@B67]\]. The presence of coronary microvascular dysfunction and this phenomenon are associated with larger infarct size, lower left ventricular ejection fraction, adverse left ventricular remodeling in the remote stage of myocardial infarction, and increased incidences of heart failure and death, compared with patients without no-reflow phenomenon\[[@B68]\]. Some studies using animal models showed that antioxidant strategies are able to reduce this phenomenon\[[@B69]-[@B71]\], and this data is consistent with a small clinical trial finding that antioxidant depletion is associated with no-reflow phenomenon in AMI\[[@B72]\]. In addition, recent research in rabbits shows that the suppression of the oxidative stress-sensitive transcription factor NF-ĸB, a key mediator of inflammation in cardiovascular systems, reduces myocardial no-reflow phenomenon\[[@B73]\].

Recently, our group has reported major clinical benefits with the use of antioxidants in pathologies associated with myocardial reperfusion, such as POAF and AMI. With regard to POAF, we documented a significant decrease in the incidence of this arrhythmia in patients undergoing cardiac surgery with extracorporeal circulation after administration of ascorbate, alpha-tocopherol, and omega-3 polyunsaturated fatty acids, which was accompanied by a significant decrease in oxidative stress biomarkers in auricular tissue and peripheral blood\[[@B60]\].

ROLE OF ANTIOXIDANTS
====================

Despite a molecular basis and *in vitro* evidence supporting the use of antioxidants to prevent MRI, clinical evidence continues to be controversial. In the clinical setting, impaired micro-circulatory reperfusion was improved by ascorbate infusion in patients undergoing elective PCA\[[@B74]\]. Similar results were recently reported by our group\[[@B75]\]. These results suggest a positive role of antioxidants in counteracting the deleterious effects of oxidative stress on microvascular function. On the other hand, the ROS scavenger edaravone when administered to patients with AMI immediately prior to reperfusion, significantly reduced infarct size and reperfusion arrhythmias\[[@B76],[@B77]\]. Also some experimental studies reported that the use of deferoxamine (DFO) and N-acetylcysteine (NAC) could improve microvascular dysfunction\[[@B78],[@B79]\].

Carotenoids represent another potential pharmacological alternative in the management of MRI\[[@B80]\]. Carotenoids are a widely distributed group of fat-soluble pigments which exert antioxidant, anti-inflammatory, and antiproliferative properties\[[@B81]\]. Several experimental data support potential role of carotenoids in this pathological condition: Tong et al\[[@B81]\] demonstrated that pretreatment with lycopene reduced cardiomyocyte death induced by ischemia/reoxygenation *in vitro*, and also reduced myocardial infarct size in an *in vivo* model of AMI\[[@B82]\]. Another carotenoid, crocetin, protected against myocardial reperfusion injury *in vivo* by inhibiting ROS production, reducing eNOS expression and myocardium apoptosis\[[@B82]\]. All-trans retinoic acid presented also protective activity against reperfusion injury both *in vitro* and *in vivo*, probably by down-regulating MAPK signaling\[[@B84]\]. Despite the fact that carotenoids have been useful in preventing MRI in experimental studies and have arisen as a promising pharmacological alternative, further clinical studies and randomized clinical trials are required.

In the following paragraphs we will discuss a new hypothesis for the prevention of MRI through the combined use of ascorbate, NAC, and DFO prior to reperfusion in order to strengthen antioxidant defense systems and so prevent oxidative damage (Figure [4](#F4){ref-type="fig"}).

![Experimental, pharmacological and clinical approaches to prevent myocardial reperfusion injury at cellular level. RISK: Reperfusion injury salvage kinase pathway; SAFE: Survivor activating factor enhancement pathway; GSH: Reduced glutathione; GSSG: Oxidized glutathione; NAC: N-acetylcysteine; DFO: deferoxamine; ONOO\*: Peroxynitrite; NO: Nitric oxide; OH \*: Radical hydroxyl; mPTP: Mitochondrial permeability transition pore.](WJC-10-74-g004){#F4}

Ascorbate
---------

The basis of this hypothesis is to achieve high plasma levels of ascorbate prior to reperfusion in order to strengthen the antioxidant defense system of myocardial tissue. Thus, when oxygen suddenly arrives to the previously ischemia-damaged myocardial tissue-which is the primary substrate for the production of the highly reactive superoxide anion radical-ascorbate may efficiently reduce ROS and prevent oxidative damage\[[@B5],[@B8]\]. To support this hypothesis, we will discuss the main actions of this antioxidant and its pharmacokinetic properties.

Ascorbate is an essential antioxidant that performs its roles in different cell locations by acting in water-soluble components\[[@B85],[@B86]\]. The most studied mechanism in which ascorbate acts is partly based on its ability to directly reduce ROS\[[@B87]-[@B89]\]. Besides its ROS scavenger actions, ascorbate exerts a complex modulation of numerous enzymes involved in ROS production, endothelial dysfunction, platelet aggregation, and smooth muscle cell tone\[[@B90]-[@B92]\]. The four most important mechanisms in which ascorbate modulates the endothelial function are NADPH down-regulation, and the up-regulation of eNOS, phospholipase A2, and antioxidant enzymes. NADPH oxidase, the most important superoxide source in the cardiovascular system, can be directly down-regulated by ascorbate\[[@B91],[@B92]\]. The mechanism behind this effect has not been completely elucidated. It has been reported that ascorbate could be involved in the transcriptional and post-transcriptional modulation of NADPH oxidase\[[@B89],[@B93]\] as well as in its synthesis\[[@B94]\]. In the presence of oxidative stress, eNOS is mostly in its uncoupled form which leads to endothelial dysfunction. In this context, ascorbate has been shown to increase eNOS activity, by preventing the oxidation of tetrahydrobiopterin and by inhibiting the p47phox subunit expression\[[@B95]\]. Therefore, ascorbate increases NO synthesis, reduces ROS formation and contributes to vascular tone regulation\[[@B96]-[@B98]\]. In relation to the up-regulation of antioxidant enzymes, some studies have demonstrated a positive correlation between antioxidant vitamin and antioxidant enzyme activity, particularly SOD. The mechanisms underlying these findings are not well explained, but it is plausible to hypothesize the existence of transcriptional and post-transcriptional events involved in the up-regulation of those antioxidant enzymes\[[@B92]\].

Ascorbate counteracts and prevents the oxidation of lipids, proteins, and DNA, subsequently protecting their structure and biological function. Together with glutathione, ascorbate constitutes a primary line of defense against ROS\[[@B99]\]. Ascorbate, in aqueous compartments, can recycle α-tocopherol in membranes by reducing the α-tocopheroxyl radical back to α-tocopherol\[[@B100]\]. Accordingly, ascorbate has been shown to recycle α-tocopherol in lipid bilayers\[[@B101]\] and erythrocytes\[[@B95]\].

Ascorbate scavenging is concentration-dependent and requires intravenous administration. This is necessary because ascorbate concentration in plasma is tightly controlled and an excess of ascorbate is excreted as a function of dosage. In fact, even with supplementation approaching maximally tolerated doses, ascorbate plasma concentrations are always \< 250 µmol/L. By contrast, intravenously injected ascorbate can safely lead to concentrations of 25-30 mmol/L\[[@B102]\]. It is of interest to mention that intra-arterial administration of high doses of ascorbate has been demonstrated to abolish both *in vivo* and *in vitro* effects of the superoxide anion with respect to the impairment of vascular endothelial function in patients with essential hypertension\[[@B103]\]. Unfortunately, oral doses are not enough to scavenge superoxide anions, thus a beneficial effect should not be expected.

Our group recently developed a randomized clinical trial in patients with AMI undergoing PCA, where massive doses of ascorbate (or placebo) were administered prior to PCA. Patients treated with ascorbate prior to myocardial reperfusion showed a better recovery of ejection fraction at 2-3 mo (measured by cardiac magnetic resonance) and significantly higher myocardial perfusion after PCA (*TIMI*-myocardial perfusion grade) than placebo patients, with no differences in infarct size\[[@B75]\] (Table [1](#T1){ref-type="table"}).

###### 

Clinical trials

                                                                            **Study details**                                                                                   **Country**   ***n*** **Intervention**   **Main findings**                                                             **Ref**.                                                           
  ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------- -------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------ ---------
  AA                                                                        Ascorbate previous to elective coronary angioplasty                                                 Italy         28                         28                                                                            Decrease in oxidative stress and improves reperfusion parameters   \[74\]
  Ascorbate previous to primary coronary angioplasty in patients with AMI   Chile                                                                                               53            46                         Improve ventricular function and reperfusion No differences in infarct size   \[75\]                                                             
  NAC                                                                       N-acetylcysteine previous and after primary coronary angioplasty in patients with AMI               Germany       126                        126                                                                           Decrease in oxidative stress No differences in infarct size        \[105\]
                                                                            N-acetylcysteine and nitroglycerine previous to primary coronary angioplasty in patients with AMI   Australia     67                         65                                                                            Decrease in infarct size and cardiac damage biomarkers             \[116\]
  DFO                                                                       Deferoxamine previous and after coronary angioplasty in patients with AMI                           Australia     28                         32                                                                            Decrease in oxidative stress No differences in infarct size        \[114\]

Main clinical studies that have used ascorbate, N-acetylcysteine or deferoxamine to prevent reperfusion injury in patients affected by acute myocardial infarction and treated with coronary angioplasty. AA: Ascorbate; NAC: N-acetylcysteine; DFO: Deferoxamine; IR: Ischemia reperfusion; AMI: Acute myocardial infarction.

N-acetyl-L-cysteine
-------------------

Ascorbate consumes glutathione (GSH) to exert its antioxidant activity. High doses of ascorbate might be associated with a decrease in cellular GSH reserves\[[@B5]\]. For this reason, N-acetyl-L-cysteine (NAC) - a known GSH-donor-may also have synergistic effects with high doses of ascorbate. In the following paragraphs, we will discuss the potential role of NAC in preventing MRI.

Despite numerous studies and a prolonged track record of clinical trials, the effects of NAC are clouded in controversy and its pharmacological mechanism has not yet been fully clarified. However, there is plenty of evidence regarding its mechanism of action. First of all, NAC's main feature, and also the most studied one, is its capacity to act as a precursor for synthesis of GSH, thus replenishing GSH that has become depleted through the use of this peptide in detoxification routes\[[@B104]\]. However, it is vital to think of NAC as a pro-drug, because actions that are driven by this drug are dependent on its successful conversion to the antioxidant and detoxifying agent, GSH. Another frequently mentioned property of NAC is its intrinsic antioxidant activity. Nevertheless, the evidence regarding the antioxidant potential of NAC suggests that it does not have a noteworthy direct antioxidant activity\[[@B105]\].

NAC acts indirectly through chelation of metal ions such as catalytic iron\[[@B106],[@B107]\] giving it the capability of mediating Fenton's reaction, thus ameliorating the possibility of the formation of hydroxyl radicals. This property is due to the fact that NAC forms conjugates with some metals. However, the importance of this mechanism in driving any protective effects compared to intracellular GSH replenishing is still unclear. Current evidence agrees on the capability of NAC to act as an inhibitor of NF-κB\[[@B108]\], a transcription factor that plays a critical role in inflammation, immunity, cell proliferation, differentiation, and survival. In conclusion, molecular mechanisms by which NAC exerts its diverse effects are complex and still unclear. Although it has been shown that NAC interacts with numerous biochemical pathways, its main mechanism involves serving as a precursor of cysteine and replenishing cellular GSH levels\[[@B104]\].

NAC has been widely used in different experimental and clinical settings to counteract oxidative stress. It has been demonstrated that NAC in combination with nitroglycerin and streptokinase is associated with significantly less oxidative stress and improved preservation of left ventricular function\[[@B109]\]. However, it has also been reported that a high-dose of NAC prior to PCA, although it reduces oxidative stress, does not provide an additional advantage in the prevention of MRI\[[@B110]\]. Additionally, an interesting study published in 2006 shows that administration of NAC in combination with streptokinase significantly diminishes oxidative stress and improves left ventricular function in patients with AMI\[[@B111]\]. A recent study using a rat model of myocardial ischemia-reperfusion injury demonstrates that treatment with continuous infusion of NAC (150 mg/kg per hour) starting 30 min before occlusion and lasting for 2 h (or until 1 h after the start of reperfusion) produces a significant limitation of the infarct and allows the recovery of the decreased total glutathione when compared to control\[[@B112]\]. Recently has been published the NACIAM trial by Pasupathy et al\[[@B113]\], that demonstrated a protective effect with the use of high doses of NAC in combination with a nitric oxide donor in patients with AMI (Table [1](#T1){ref-type="table"}). This important study shows that NAC has a powerful protective effect when used in combination and previous to myocardial reperfusion. In summary, due to the known antioxidant and cardioprotective effect and its role as GSH-donor, it is plausible to suggest that NAC might have a synergistic effect with high doses of ascorbate and deferoxamine to prevent MRI.

Deferoxamine
------------

Given the known role of iron in the lethal reperfusion, iron chelators have been tested to ameliorate this injury. One of the most frequently used drugs for this purpose is DFO. The first reports of its use to improve cardiac function in myocardium iron overload by directly removing iron from the myocardium\[[@B114]\] date from 1980s\[[@B115]\]. In animal models of AMI, the use of DFO has exhibited positive results. Some studies performed in dogs reported a decrease in the infarct size when they used DFO during the reperfusion, suggesting that iron-catalyzed production of ROS contributes to cardiomyocyte necrosis in the setting of MRI\[[@B116],[@B117]\]. Studies have described improved recovery of myocardial function after ischemia, by using iron chelation\[[@B36],[@B118]\]. The results obtained from animal models of MRI have suggested the use of iron chelators in the human model with partial results to date. Paraskevaidis et al\[[@B119]\] suggested DFO infusion was able to reduce myocardial stunning after elective coronary artery bypass grafting and to improve long-term ejection fraction. In a recent clinical study, Chan et al\[[@B120]\] randomized patients with STEMI to intravenous deferoxamine before coronary angioplasty and then for 12 h *vs* placebo (Table [1](#T1){ref-type="table"}). The serum iron levels and lipid peroxidation biomarkers were reduced in the DFO-group without differences in the infarct size. The role of iron and ascorbate in the MRI has become of increasing interest in the last few years. It has been demonstrated that the combined use of DFO and ascorbate prevent reperfusion arrhythmias\[[@B121]\].

As has been previously discussed, cumulated evidence from both experimental and clinical studies leads us to support the view that a novel combined antioxidant strategy could limit MRI and its consequences. This novel hypothesis is based on the combined use of antioxidants prior to the reperfusion therapy in order to limit the oxidative challenge during reperfusion. The key points of this novel intervention are: (1) To achieve high plasma concentrations of ascorbate through massive intravenous doses to counteract the ROS and RNS production; (2) the use of NAC to prevent GSH depletion; and (3) the use of DFO to diminish the catalytic free iron levels in order to prevent the ROS production by the Fenton reaction.

Accordingly, in our laboratory recent studies of the murine Langendorff model have been conducted to determine the effect of antioxidants in MRI. We are now studying the effect of ascorbate, NAC, and DFO used alone and in association. Under these conditions, we expect a lower vulnerability of the myocardial tissue to the reperfusion injury associated with oxidative stress. This protective effect could be expressed by a lower infarct size, reduced post-reperfusion arrhythmias and myocardial stunning occurrence, and improved microvascular function. Finally, at present, there is no evidence available from any trial that has applied this antioxidant protocol to diminish MRI. Table [1](#T1){ref-type="table"} shows a summary of the main clinical studies that have used antioxidants to prevent MRI in patients with AMI.

CONCLUSION
==========

There is major evidence with respect to the contribution of oxidative stress to MRI in cardiovascular diseases. Despite the many significant advances in the understanding of the mechanisms of MRI, it remains an unsolved problem. There is a lack of consistency between basic studies and clinical trials aimed to reduce MRI through antioxidant therapies. Although promising results have been obtained in experimental studies (mainly in animal models), these benefits have not been translated into clinical settings. It is noteworthy that the administration of high ascorbate doses prior to reperfusion and also NAC administration appear to be safe and rational therapies against the development of oxidative damage associated with myocardial reperfusion. Furthermore, ascorbate association with NAC and DFO could improve the beneficial effect of ascorbate, making it even more effective in preventing myocardial reperfusion damage associated with PCA following AMI.
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